In the second of this special two podcast celebrating our twentieth anniversary, hear from Visiopharm founder and CEO Michael Grunkin.

In part one of our special two part podcast celebrating our twentieth anniversary, hear from Visiopharm founder and CEO Michael Grunkin.

Cancer immunotherapy, also known as immuno-oncology is tapping into the power of our own immune system to fight cancer. There are multiple processes and immune cell populations involved in tumor immunology and digital pathology and whole slide imaging has allowed scientists to leverage the power of tissue image analysis to detect and quantify them. In this episode, Dr Aleksandra Zuraw is joined by Prof Elfriede Noessner who explains the complexities of the immune system, how it is being influenced to cure cancer and what role tissue image analysis plays in the process.

In the final episode of our three part series about phenotyping, Dr Aleksandra Zuraw and our Scientific Consulting Sales Manager, Regan Baird, discuss what to consider when choosing a image analysis solution for phenotyping.

In the second of our series about phenotyping with Dr Aleksandra Zuraw and our Scientific Consulting Sales Manager, Regan Baird, find out how to make sense of multiplex data with phenotyping.

In this episode, Dr Aleksandra Zuraw looks at the complicated maze of digital pathology reimbursement and how to align it with its value. She speaks to Visiopharm's Chief Clinical and Regulatory Officer, Esther Abels, who contributed to establishing a regulatory pathway for digital pathology. Esther tells us about the importance of supporting the understanding of the health economic impacts and patient improvements. “We need to start thinking about is to articulate what the services is that we provide and what is it then that it's uniquely provided to the individual patients. And we need to identify what is the data that we need to figure this out and to make sure that not only the fee goes for the technology, component of the code, but also to the physician’s fee. I think what we should be doing is defining key endpoints and outcomes, and that we have to outline these relevant to demonstration of the value, and of the technology.” Esther Abels, Chief Clinical and Regulatory Officer at Visiopharm

In this episode, Dr Aleksandra Zuraw speaks to David Harrison, a pathology professor at the University of St Andrews in Scotland, and a member of Visiopharm's scientific advisory board, about artificial intelligence and why pathologists should embrace it in their work.

With AI developing at an increasingly rapid pace, as we kick off a new year, we ask: Why and how is AI taking over the tissue image analysis field? Listen to learn about: • What’s changed in AI image analysis • The differences between classical image analysis v AI image analysis • The benefits of deep learning AI • How AI image analysis can be performed without previous image analysis experience • What’s next for AI image analysis

Implementing digital pathology into clinical practice is a big endeavor and a decision not taken lightly by pathology laboratories. In today’s episode’s guest, Dr. Ralf Huss, the chairman of Visiopharm’s advisory board, is sharing his view on why and how digital pathology should be implemented into clinical practice. His unique perspective comes from all corners of the pathology world, from academia, through big pharma, small startups all the way to hospital practice. He explains; • What the biggest benefits of going digital are • How to start • And why eventually, pathologists will be forced to accept the digital transformation.